JP6283031B2 - 遺伝学的に修飾された非ヒト動物およびその使用法 - Google Patents

遺伝学的に修飾された非ヒト動物およびその使用法 Download PDF

Info

Publication number
JP6283031B2
JP6283031B2 JP2015531224A JP2015531224A JP6283031B2 JP 6283031 B2 JP6283031 B2 JP 6283031B2 JP 2015531224 A JP2015531224 A JP 2015531224A JP 2015531224 A JP2015531224 A JP 2015531224A JP 6283031 B2 JP6283031 B2 JP 6283031B2
Authority
JP
Japan
Prior art keywords
human
cells
genetically modified
mice
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015531224A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015529083A (ja
JP2015529083A5 (enExample
Inventor
リチャード エイ． フラベル
リチャード エイ． フラベル
マルクス マンツ
マルクス マンツ
アンソニー ロンヴォークス
アンソニー ロンヴォークス
ティル ストロウィッグ
ティル ストロウィッグ
ティム ウィリンガー
ティム ウィリンガー
アンドリュー ジェイ． マーフィー
アンドリュー ジェイ． マーフィー
ショーン スティーブンズ
ショーン スティーブンズ
ジョージ ヤンコポーロス
ジョージ ヤンコポーロス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Regeneron Pharmaceuticals Inc
Original Assignee
Yale University
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University, Regeneron Pharmaceuticals Inc filed Critical Yale University
Publication of JP2015529083A publication Critical patent/JP2015529083A/ja
Publication of JP2015529083A5 publication Critical patent/JP2015529083A5/ja
Application granted granted Critical
Publication of JP6283031B2 publication Critical patent/JP6283031B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0387—Animal model for diseases of the immune system

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2015531224A 2012-09-07 2013-09-06 遺伝学的に修飾された非ヒト動物およびその使用法 Active JP6283031B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261698002P 2012-09-07 2012-09-07
US61/698,002 2012-09-07
US201361775171P 2013-03-08 2013-03-08
US61/775,171 2013-03-08
PCT/US2013/058448 WO2014039782A2 (en) 2012-09-07 2013-09-06 Genetically modified non-human animals and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018010192A Division JP6517958B2 (ja) 2012-09-07 2018-01-25 遺伝学的に修飾された非ヒト動物およびその使用法

Publications (3)

Publication Number Publication Date
JP2015529083A JP2015529083A (ja) 2015-10-05
JP2015529083A5 JP2015529083A5 (enExample) 2017-10-05
JP6283031B2 true JP6283031B2 (ja) 2018-02-21

Family

ID=50237767

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015531224A Active JP6283031B2 (ja) 2012-09-07 2013-09-06 遺伝学的に修飾された非ヒト動物およびその使用法
JP2018010192A Active JP6517958B2 (ja) 2012-09-07 2018-01-25 遺伝学的に修飾された非ヒト動物およびその使用法
JP2019079029A Active JP6732998B2 (ja) 2012-09-07 2019-04-18 遺伝学的に修飾された非ヒト動物およびその使用法
JP2020117482A Active JP7066785B2 (ja) 2012-09-07 2020-07-08 遺伝学的に修飾された非ヒト動物およびその使用法
JP2022072893A Active JP7605789B2 (ja) 2012-09-07 2022-04-27 遺伝学的に修飾された非ヒト動物およびその使用法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018010192A Active JP6517958B2 (ja) 2012-09-07 2018-01-25 遺伝学的に修飾された非ヒト動物およびその使用法
JP2019079029A Active JP6732998B2 (ja) 2012-09-07 2019-04-18 遺伝学的に修飾された非ヒト動物およびその使用法
JP2020117482A Active JP7066785B2 (ja) 2012-09-07 2020-07-08 遺伝学的に修飾された非ヒト動物およびその使用法
JP2022072893A Active JP7605789B2 (ja) 2012-09-07 2022-04-27 遺伝学的に修飾された非ヒト動物およびその使用法

Country Status (18)

Country Link
US (6) US9820476B2 (enExample)
EP (3) EP4606818A3 (enExample)
JP (5) JP6283031B2 (enExample)
KR (7) KR102287541B1 (enExample)
CN (4) CN113897398B (enExample)
AU (3) AU2013312359B8 (enExample)
CA (1) CA2881468C (enExample)
DK (1) DK2892330T3 (enExample)
ES (2) ES3034290T3 (enExample)
FI (1) FI2892330T3 (enExample)
IL (4) IL307969B1 (enExample)
IN (1) IN2015DN02032A (enExample)
MX (2) MX364714B (enExample)
NZ (3) NZ741951A (enExample)
PT (1) PT2892330T (enExample)
RU (2) RU2642319C2 (enExample)
SG (2) SG11201500504RA (enExample)
WO (1) WO2014039782A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010303737B2 (en) 2009-10-06 2014-05-29 Institute For Research In Biomedicine (Irb) Genetically modified mice and engraftment
MY162984A (en) 2011-02-15 2017-07-31 Regeneron Pharma Humanized m-csf mice
SG11201500504RA (en) 2012-09-07 2015-02-27 Univ Yale Genetically modified non-human animals and methods of use thereof
EP2914102B1 (en) 2012-11-05 2017-10-18 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals and methods of use thereof
LT3175706T (lt) 2013-09-23 2019-02-25 Regeneron Pharmaceuticals, Inc. Gyvūnai, išskyrus žmogų, turintys humanizuotą signalą reguliuojančio baltymo geną
LT3138397T (lt) 2013-10-15 2019-04-10 Regeneron Pharmaceuticals, Inc. Humanizuoti il-15 gyvūnai
WO2015077072A1 (en) 2013-11-19 2015-05-28 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized a proliferation-inducing ligand gene
BR112016025751A2 (pt) 2014-05-05 2018-01-16 Regeneron Pharma roedor, e, métodos para fabricar um roedor e um camundongo humanizados e para identificar um composto capaz de modular a ativação de complemento
NO2785538T3 (enExample) 2014-05-07 2018-08-04
KR102627332B1 (ko) 2014-05-19 2024-01-26 리제너론 파마슈티칼스 인코포레이티드 인간 epo를 발현하는 유전자 변형된 비-인간 동물
ES2969389T3 (es) 2014-12-05 2024-05-17 Regeneron Pharma Animales no humanos que tienen un gen del grupo de diferenciación 47 humanizado
WO2016094481A1 (en) 2014-12-09 2016-06-16 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cluster of differentiation 274 gene
JP6830437B2 (ja) 2014-12-10 2021-02-17 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 疾患を処置するための遺伝子改変された細胞、組織および臓器
KR102658190B1 (ko) 2015-04-13 2024-04-17 리제너론 파마슈티칼스 인코포레이티드 인간화된 sirpa-il15 녹인 마우스 및 이의 이용 방법
RS61866B1 (sr) 2015-11-20 2021-06-30 Regeneron Pharma Ne-humane životinje koje imaju humanizovani gen za aktivaciju limfocita 3
KR102487839B1 (ko) 2016-02-04 2023-01-12 리제너론 파마슈티칼스 인코포레이티드 조작된 angptl8 유전자를 갖는 비인간 동물
RU2749715C2 (ru) 2016-02-29 2021-06-16 Регенерон Фармасьютикалз, Инк. Грызуны, характеризующиеся гуманизированным геном tmprss
CN106119284A (zh) * 2016-06-27 2016-11-16 北京维通达生物技术有限公司 一种用于构建免疫缺陷动物模型的产品及其应用
US20190320633A1 (en) * 2016-11-30 2019-10-24 The Jackson Laboratory Humanized mouse model with improved human innate immune cell development
EP3621433B1 (en) * 2017-05-12 2022-07-27 The Jackson Laboratory Nsg mice lacking mhc class i and class ii
KR20250151540A (ko) 2018-07-16 2025-10-21 리제너론 파마슈티칼스 인코포레이티드 Ditra 질환의 비인간 동물 모델 및 이의 용도
US20210355501A1 (en) * 2018-09-24 2021-11-18 Albert Einstein College Of Medicine Interleukin-8 for maintenance of human acute myeloid leukemia and myelodysplastic syndrome and uses thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN111073907B (zh) * 2018-12-25 2025-07-29 百奥赛图江苏基因生物技术有限公司 人源化细胞因子csf1基因改造非人动物的构建方法及应用
CN111118019B (zh) * 2018-12-25 2021-03-16 百奥赛图江苏基因生物技术有限公司 人源化细胞因子il3基因改造非人动物的构建方法及应用
WO2021011853A2 (en) * 2019-07-17 2021-01-21 Yale University Genetically modified non-human animals and methods of use thereof
WO2021083366A1 (en) * 2019-11-01 2021-05-06 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with human or chimeric thpo
US11339279B2 (en) * 2020-04-01 2022-05-24 Chevron Phillips Chemical Company Lp Dual catalyst system for producing LLDPE and MDPE copolymers with long chain branching for film applications
WO2022222958A1 (en) * 2021-04-20 2022-10-27 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric genes
IL318159A (en) 2022-07-19 2025-03-01 Regeneron Pharma Genetically modified animal model and its use to model the human immune system
AU2024304358A1 (en) 2023-06-16 2025-11-06 Regeneron Pharmaceuticals, Inc. Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
US20250255282A1 (en) 2024-02-08 2025-08-14 Regeneron Pharmaceuticals, Inc. Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
WO2025212991A1 (en) 2024-04-05 2025-10-09 Regeneron Pharmaceuticals, Inc. Rodent models of disease

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US5573930A (en) 1985-02-05 1996-11-12 Cetus Oncology Corporation DNA encoding various forms of colony stimulating factor-1
HU215241B (hu) 1986-10-24 1998-11-30 Cetus Corp. Eljárás telepstimuláló faktor-1 új formáinak előállítására, valamint az eljárásban alkalmazható expressziós kazetta, vektor és rekombináns gazdasejtek előállítására
EP0322240B1 (en) 1987-12-23 1995-03-01 The Board Of Trustees Of The Leland Stanford Junior University Chimeric immunocompromised mammals and their use
JP2981486B2 (ja) 1988-06-14 1999-11-22 メディカル・バイオロジー・インスティチュート 哺乳動物の免疫系研究方法
US5849288A (en) 1990-01-15 1998-12-15 Yeda Research And Development Co. Ltd. Method for production of monoclonal antibodies in chimeric mice or rats having xenogeneic antibody-producing cells
US5652373A (en) 1990-01-15 1997-07-29 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
DK0438053T3 (da) 1990-01-15 1999-11-22 Yeda Res & Dev Varig transplantation og udvikling af humane hæmopoietiske cellelinjer i normale pattedyr
ATE140480T1 (de) 1990-05-03 1996-08-15 Systemix Inc Menschliches lymph-gewebe in einem wirt mit angegriffenem immunsystem
EP0484512A4 (en) 1990-05-25 1993-05-05 Systemix, Inc. Human peripheral blood cells in an immunocompromised host
US5633426A (en) 1990-05-25 1997-05-27 Systemix, Inc. In vivo use of human bone marrow for investigation and production
EP0571525A1 (en) 1991-02-11 1993-12-01 OMMAYA, Ayub K. Spinal fluid driven artificial organ
US5222982A (en) 1991-02-11 1993-06-29 Ommaya Ayub K Spinal fluid driven artificial organ
EP0517199A1 (en) 1991-06-04 1992-12-09 Yeda Research And Development Company, Ltd. Durable engraftment of human tissue and cells in normal mammals
WO1993005796A1 (en) 1991-09-19 1993-04-01 The Scripps Research Institute Method for producing human antibodies in a non-human animal, and animals therefor
EP0539970B1 (en) 1991-10-30 1999-05-26 Idemitsu Kosan Company Limited Methods for producing human lymphocytes and human monoclonal antibodies, and human monoclonal antibodies produced thereby
US6353150B1 (en) 1991-11-22 2002-03-05 Hsc Research And Development Limited Partnership Chimeric mammals with human hematopoietic cells
WO1993018144A1 (en) 1992-03-05 1993-09-16 The Trustees Of Columbia University Of The City Of New York Recombination activating gene deficient animal
US5866757A (en) 1992-06-02 1999-02-02 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
US6018096A (en) 1993-05-03 2000-01-25 Surrogen, Inc. Animal model for engraftment, proliferation and differentiation of human hematopoietic stem cells
CA2103693A1 (en) 1993-08-06 1995-02-07 Steven Gallinger Animal model of the human immune system
JPH10503092A (ja) 1994-07-27 1998-03-24 メルク エンド カンパニー インコーポレーテッド ブラジキニンｂ２受容体が改変されたトランスジェニック非ヒト動物
US6455756B1 (en) 1994-08-12 2002-09-24 Novartis Ag Long term xenogeneic myeloid and lymphoid cell production in chimeric immunocompromised mice
US7273753B2 (en) 1996-08-02 2007-09-25 Center Of Blood Research Purification and uses of dendritic cells and monocytes
US6248721B1 (en) 1997-04-09 2001-06-19 Lung-Ji Chang Method of using mouse model for evaluation of HIV vaccines
IL132164A0 (en) 1997-04-09 2001-03-19 Chang Lung Ji Animal model for evaluation of vaccines
US20030028911A1 (en) 1999-08-31 2003-02-06 Manley Huang Transgenic mammal capable of facilitating production of donor-specific functional immunity
JP2003508038A (ja) 1999-08-31 2003-03-04 ジェネンコア インターナショナル インコーポレーテッド ドナー特異的機能性免疫の産生を容易にすることができるトランスジェニック哺乳類
AU2066301A (en) 1999-12-09 2001-06-18 Human Genome Sciences, Inc. Il-6 like polynucleotide
US6864061B2 (en) 2000-09-14 2005-03-08 Genetrol Biotherapeutics, Inc. Method for screening compounds for anti-inflammatory activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN1553963A (zh) * 2001-07-10 2004-12-08 ǿ����ǿ���о����޹�˾ 用于遗传修饰造血祖细胞的方法和这些被修饰细胞的应用
AU2002363322A1 (en) 2001-10-26 2003-05-19 Large Scale Biology Corporation Endothelial cell derived hemotopoietic growth factor
EP1452093A4 (en) 2001-11-15 2007-08-15 Kirin Brewery CHIMESE NON-MENTAL ANIMAL
AU2003281309A1 (en) 2002-07-05 2004-01-23 Kirin Beer Kabushiki Kaisha Novel undifferentiated stem cells contained in cord blood, bone marrow, peripheral blood or the like
CN101250553A (zh) 2002-07-13 2008-08-27 上海医学遗传研究所 一种促人血小板生成素表达载体及其构建方法
US20040128703A1 (en) 2002-09-09 2004-07-01 Hiroaki Shizuya Methods and compositions for the generation of humanized mice
EP1418185A1 (en) 2002-11-11 2004-05-12 Aventis Pharma Deutschland GmbH Use of EDG2 receptor in an animal model of heart failure
US20060179501A1 (en) 2002-12-16 2006-08-10 Chan Andrew C Transgenic mice expressing human cd20
DK2767161T3 (en) 2004-10-19 2018-05-07 Regeneron Pharma Method of generating an animal homozygous for genetic modification
US7759541B2 (en) 2004-12-13 2010-07-20 Iti Life Sciences Transgenic animals for assessing drug metabolism and toxicity
GB2434578A (en) 2006-01-26 2007-08-01 Univ Basel Transgenic animals
HUE030903T2 (en) 2006-04-25 2017-06-28 Univ California Administration of growth factors for the treatment of CNS disorders
EP1878342A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses
WO2008060360A2 (en) 2006-09-28 2008-05-22 Surmodics, Inc. Implantable medical device with apertures for delivery of bioactive agents
EP2088854A1 (en) 2006-12-05 2009-08-19 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Improved xenogenic immune system in a non-human mammal
AU2008262487B2 (en) 2007-05-23 2013-10-31 Sangamo Therapeutics, Inc. Methods and compositions for increased transgene expression
GB0718029D0 (en) 2007-09-14 2007-10-24 Iti Scotland Ltd Two step cluster deletion and humanisation
US20110118446A1 (en) 2007-09-28 2011-05-19 The General Hospital Corporation Methods and compositions for antibody production
US20100239578A1 (en) * 2007-10-11 2010-09-23 University Health Network Modulation of sirp-alpha - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor
JP2011510750A (ja) 2008-01-29 2011-04-07 クライマン、ギルバート・エイチ 薬物送達デバイス、キット及びそれらの方法
US20120251528A1 (en) * 2009-06-29 2012-10-04 Leskov Ilya B Non-Human Mammal Model Of Human Hematopoietic Cancer
SG10201403703XA (en) * 2009-06-29 2014-10-30 Qingfeng Chen Methods of producing humanized non-human mammals
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
AU2010303737B2 (en) 2009-10-06 2014-05-29 Institute For Research In Biomedicine (Irb) Genetically modified mice and engraftment
US9402377B2 (en) 2010-09-20 2016-08-02 Yale University Human SIRPAalpha transgenic animals and their methods of use
WO2012051572A1 (en) 2010-10-15 2012-04-19 Massachusetts Institute Of Technology A humanized non-human mammal model of malaria and uses thereof
MY162984A (en) 2011-02-15 2017-07-31 Regeneron Pharma Humanized m-csf mice
IN2014CN03920A (enExample) 2011-10-28 2015-09-04 Regeneron Pharma
SG11201500504RA (en) 2012-09-07 2015-02-27 Univ Yale Genetically modified non-human animals and methods of use thereof
EP2914102B1 (en) 2012-11-05 2017-10-18 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals and methods of use thereof
LT3175706T (lt) 2013-09-23 2019-02-25 Regeneron Pharmaceuticals, Inc. Gyvūnai, išskyrus žmogų, turintys humanizuotą signalą reguliuojančio baltymo geną
LT3138397T (lt) 2013-10-15 2019-04-10 Regeneron Pharmaceuticals, Inc. Humanizuoti il-15 gyvūnai
KR102627332B1 (ko) 2014-05-19 2024-01-26 리제너론 파마슈티칼스 인코포레이티드 인간 epo를 발현하는 유전자 변형된 비-인간 동물
KR102658190B1 (ko) 2015-04-13 2024-04-17 리제너론 파마슈티칼스 인코포레이티드 인간화된 sirpa-il15 녹인 마우스 및 이의 이용 방법

Also Published As

Publication number Publication date
EP4606818A2 (en) 2025-08-27
US11026408B2 (en) 2021-06-08
KR20150052274A (ko) 2015-05-13
IL307969A (en) 2023-12-01
AU2013312359B8 (en) 2019-08-15
US20210368752A1 (en) 2021-12-02
JP2019110922A (ja) 2019-07-11
IL282472B1 (en) 2023-12-01
KR102241962B1 (ko) 2021-04-20
US12127537B2 (en) 2024-10-29
EP4193834B1 (en) 2025-05-14
EP2892330A4 (en) 2016-07-27
IL282472A (en) 2021-06-30
PT2892330T (pt) 2023-02-17
EP4606818A3 (en) 2025-10-22
JP6517958B2 (ja) 2019-05-22
RU2015112607A (ru) 2016-10-27
CN104955326B (zh) 2018-07-20
CN108782459B (zh) 2021-11-05
JP7605789B2 (ja) 2024-12-24
IL265570B (en) 2021-05-31
AU2013312359B2 (en) 2019-05-23
US20180020647A1 (en) 2018-01-25
HK1211176A1 (en) 2016-05-20
WO2014039782A3 (en) 2015-07-23
AU2021240324A1 (en) 2021-10-28
RU2017145913A3 (enExample) 2021-08-16
JP2015529083A (ja) 2015-10-05
NZ746089A (en) 2020-05-29
KR20220164808A (ko) 2022-12-13
KR102645622B1 (ko) 2024-03-11
CN104955326A (zh) 2015-09-30
CN108782459A (zh) 2018-11-13
KR102340059B1 (ko) 2021-12-17
KR102473555B1 (ko) 2022-12-05
ES3034290T3 (en) 2025-08-14
RU2768282C2 (ru) 2022-03-23
KR20230153500A (ko) 2023-11-06
CA2881468A1 (en) 2014-03-13
FI2892330T3 (fi) 2023-03-25
MX2019005251A (es) 2019-08-05
MX385035B (es) 2025-03-14
CN120718856A (zh) 2025-09-30
SG11201500504RA (en) 2015-02-27
KR102594390B1 (ko) 2023-10-27
JP7066785B2 (ja) 2022-05-13
CN113897398A (zh) 2022-01-07
KR20210156846A (ko) 2021-12-27
US20250072405A1 (en) 2025-03-06
US9820476B2 (en) 2017-11-21
DK2892330T3 (da) 2023-01-30
JP2018088925A (ja) 2018-06-14
IL282472B2 (en) 2024-04-01
US20190082663A1 (en) 2019-03-21
JP2020168024A (ja) 2020-10-15
IN2015DN02032A (enExample) 2015-08-14
EP2892330A2 (en) 2015-07-15
IL236877A0 (en) 2015-03-31
IL265570A (en) 2019-05-30
AU2013312359A8 (en) 2019-08-15
CN113897398B (zh) 2025-07-08
IL307969B1 (en) 2025-10-01
US10433527B2 (en) 2019-10-08
AU2019216625A1 (en) 2019-09-05
AU2013312359A1 (en) 2015-02-19
RU2017145913A (ru) 2019-02-19
EP2892330B1 (en) 2022-11-23
US20150208622A1 (en) 2015-07-30
MX2015002983A (es) 2015-06-17
EP4193834C0 (en) 2025-05-14
ES2938342T3 (es) 2023-04-10
NZ741951A (en) 2020-04-24
CA2881468C (en) 2023-03-21
AU2021240324B2 (en) 2024-02-22
KR20210044315A (ko) 2021-04-22
SG10201701759VA (en) 2017-04-27
KR102287541B1 (ko) 2021-08-10
AU2019216625B2 (en) 2021-07-08
MX364714B (es) 2019-05-06
NZ704957A (en) 2018-05-25
JP2022105531A (ja) 2022-07-14
KR20240045263A (ko) 2024-04-05
US20200093105A1 (en) 2020-03-26
JP6732998B2 (ja) 2020-07-29
EP4193834A1 (en) 2023-06-14
WO2014039782A2 (en) 2014-03-13
KR20210099664A (ko) 2021-08-12
RU2642319C2 (ru) 2018-01-24

Similar Documents

Publication Publication Date Title
JP7605789B2 (ja) 遺伝学的に修飾された非ヒト動物およびその使用法
HK40095010B (en) Methods of using genetically modified mice
HK40095010A (en) Methods of using genetically modified mice
HK1211176B (en) Genetically modified mice and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160622

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170412

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170417

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170822

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20170822

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180119

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180125

R150 Certificate of patent or registration of utility model

Ref document number: 6283031

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250